PI-RADSv2与定量表观扩散系数在考虑前列腺癌主动监测患者中预测确诊活检结果的表现
该回顾性研究纳入371例临床低危前列腺癌患者,在确诊活检前行3T前列腺MRI,评估PI-RADSv2与ADC预测活检升级的表现。确诊活检中107/371(29%)患者出现Gleason评分升级。PI-RADSv2预测活检升级的准确率显著高于ADC(p=0.014),联合评分未优于单独PI-RADSv2。
要点
- PI-RADSv2预测确诊活检Gleason升级的准确率显著高于ADC(p=0.014)。
- PI-RADSv2≤3分者中12/232(5%)确诊活检遗漏Gleason评分升级。
- PI-RADSv2+ADC联合评分未优于单独PI-RADSv2。
核心结论
- PI-RADSv2在预测确诊活检前列腺癌升级方面优于ADC测量。
- 联合PI-RADSv2与ADC的复合评分未较单独PI-RADSv2表现更好。
研究设计与样本
- 经IRB批准的回顾性研究,纳入371例连续临床低危前列腺癌男性(初始活检Gleason评分≤6、前列腺特异性抗原<10 ng/ml、临床分期≤T2a)。
- 所有患者在确诊活检前行3T前列腺MRI,由两名独立放射科医生记录PI-RADSv2评分并测量相应ADC值。
- 生成复合评分以评估PI-RADSv2+ADC联合应用的表现。
关键影像表现/征象
- 确诊活检中107/371(29%)患者出现前列腺癌Gleason评分升级。
诊断标准与关键数值
- PI-RADSv2预测活检升级的准确率85%、敏感度89%、特异度83%、阳性预测值68%、阴性预测值95%。
- ADC预测活检升级的准确率78%、敏感度82%、特异度76%、阳性预测值58%、阴性预测值91%。
- PI-RADSv2预测活检升级的准确率显著高于ADC(p=0.014)。
- PI-RADSv2评分≤3分者中12/232(5%)患者确诊活检遗漏Gleason评分升级。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To assess the performance of the updated Prostate Imaging Reporting and Data System (PI-RADSv2) and the apparent diffusion coefficient (ADC) for predicting confirmatory biopsy results in patients considered for active surveillance of prostate cancer (PCA).
METHODS: IRB-approved, retrospective study of 371 consecutive men with clinically low-risk PCA (initial biopsy Gleason score ≤6, prostate-specific antigen <10 ng/ml, clinical stage ≤T2a) who underwent 3T-prostate MRI before confirmatory biopsy. Two independent radiologists recorded the PI-RADSv2 scores and measured the corresponding ADC values in each patient. A composite score was generated to assess the performance of combining PI-RADSv2 + ADC.
RESULTS: PCA was upgraded on confirmatory biopsy in 107/371 (29%) patients. Inter-reader agreement was substantial (PI-RADSv2: k = 0.73; 95% CI [0.66-0.80]; ADC: r = 0.74; 95% CI [0.69-0.79]). Accuracies, sensitivities, specificities, positive predicted value and negative predicted value of PI-RADSv2 were 85, 89, 83, 68, 95 and 78, 82, 76, 58, 91% for ADC. PI-RADSv2 accuracy was significantly higher than that of ADC for predicting biopsy upgrade (p = 0.014). The combined PI-RADSv2 + ADC composite score did not perform better than PI-RADSv2 alone. Obviating biopsy in patients with PI-RADSv2 score ≤3 would have missed Gleason Score upgrade in 12/232 (5%) of patients.
CONCLUSION: PI-RADSv2 was superior to ADC measurements for predicting PCA upgrading on confirmatory biopsy.
引用
- Nougaret S, Robertson N, Golia Pernicka J, et al. The performance of PI-RADSv2 and quantitative apparent diffusion coefficient for predicting confirmatory prostate biopsy findings in patients considered for active surveillance of prostate cancer. Abdom Radiol (NY). 2017. PMID: 28258355. doi:10.1007/s00261-017-1086-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。